<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
         xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         dtd-version="1.1"
         xml:lang="sl"
         article-type="other">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
         <journal-title-group>
            <journal-title>Zdravniški vestnik</journal-title>
            <trans-title-group xml:lang="en">
               <trans-title>Slovenian Medical Journal</trans-title>
            </trans-title-group>
            <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
         </journal-title-group>
         <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
         <issn publication-format="epub" pub-type="epub">1581-0224</issn>
         <issn-l>0350-0063</issn-l>
         <publisher>
            <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
            <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
            <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.6016/ZdravVestn.2646</article-id>
         <article-id pub-id-type="publisher-id">2646</article-id>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Metabolic and hormonal disorders</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="discipline" xml:lang="sl">
               <subject>Medicina/Zdravstvo</subject>
               <subj-group>
                  <subject>Metabolne in hormonske motnje</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Professional article</subject>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="sl">
               <subject>Strokovni članek</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="sl">
               <subject>Metabolne in hormonske motnje</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="sl">Obravnava otrok, okuženih z bakterijo Helicobacter pylori</article-title>
            <trans-title-group>
               <trans-title xml:lang="en">Approach to Helicobacter pylori infection in paediatric population</trans-title>
            </trans-title-group>
            <alt-title alt-title-type="running-head" xml:lang="sl">Obravnava otrok, okuženih z bakterijo Helicobacter pylori</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Homan</surname>
                  <given-names>Matjaž</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="corresp" rid="corr"/>
            </contrib>
         </contrib-group>
         <aff-alternatives id="aff1">
            <aff xml:lang="sl">
               <label>1</label>
               <institution>Klinični oddelek za gastroenterologijo, hepatologijo in nutricionistiko, Pediatrična klinika, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>1</label>
               <institution>Unit of Gastroenterology and Hepatology, Division of Paediatrics, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <author-notes>
            <fn fn-type="conflict" xml:lang="en">
               <p>The authors have declared that no competing interests exist.</p>
            </fn>
            <fn fn-type="conflict" xml:lang="sl">
               <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
            </fn>
            <corresp id="corr">Matjaž Homan, e-mail: <email xlink:type="simple"/>
            </corresp>
         </author-notes>
         <pub-date pub-type="ppub">
            <month>8</month>
            <year>2018</year>
         </pub-date>
         <pub-date pub-type="epub">
            <month>8</month>
            <year>2018</year>
         </pub-date>
         <volume>87</volume>
         <issue>7–8</issue>
         <fpage>378</fpage>
         <lpage>84</lpage>
         <history>
            <date date-type="received">
               <day>26</day>
               <month>8</month>
               <year>2017</year>
            </date>
            <date date-type="accepted">
               <day>28</day>
               <month>11</month>
               <year>2017</year>
            </date>
         </history>
         <permissions>
            <copyright-statement xml:lang="en">Copyright © 2018, Slovenian Medical Association (SZD)</copyright-statement>
            <copyright-statement xml:lang="sl">© 2018, Slovensko zdravniško društvo (SZD)</copyright-statement>
            <copyright-year>2018</copyright-year>
            <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
            <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="en">
               <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
            </license>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="sl">
               <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
            </license>
         </permissions>
         <abstract xml:lang="sl">
            <title>Izvleček</title>
            <p>Prevalenca okužbe z bakterijo <italic toggle="yes">Helicobacter pylori</italic> v razvitem svetu je nižja od 20 %. Ta okužba pri otrocih v večini primerov povzroči kronični gastritis brez simptomov. Kronične bolečine v trebuhu, če ob endoskopiji zgornjih prebavil ne odkrijemo erozij ali ulkusov, pri otrocih niso povezane z bakterijsko okužbo. Glede na to ni priporočljivo diagnosticiranje okužbe s <italic toggle="yes">Helicobacter pylori</italic> z neinvazivnimi testi v otroštvu. Zdravljenje naj se usmeri glede na antibiotično odpornost seva bakterije, ki smo jo osamili iz biopta želodčne sluznice ob endoskopiji zgornjih prebavil. V članku so povzeta priporočila, ki jih je ob sodelovanju avtorja članka oblikoval letos Odbor za okužbo z bakterijo <italic toggle="yes">Helicobacter pylori</italic> v okviru Severnoameriškega in Evropskega pediatričnega združenja za gastroenterologijo, hepatologijo in prehrano (NASPGHAN, ESPGHAN) na osnovi sistematičnega pregleda objavljenih raziskav s tega področja.</p>
         </abstract>
         <trans-abstract xml:lang="en">
            <title>Abstract</title>
            <p>Prevalence of <italic toggle="yes">Helicobacter pylori</italic> infection has decreased significantly in recent years, especially in the developed world where it dropped below 20 %. In the majority of cases in children, <italic toggle="yes">Helicobacter pylori</italic> causes asymptomatic chronic gastritis. Systematic reviews and meta-analysis showed that recurrent abdominal pains in children are not associated with bacterial infection. Therefore “test and treat” strategy is not recommended in paediatric population. Eradication therapy should be prescribed according to antimicrobial sensitivity of the bacterial strain obtained during endoscopy. The article summarizes recent recommendations and guidelines of the joint North American and European Society of Paediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN, ESPGHAN) published this year and based on the systemic review of published studies from the field.</p>
         </trans-abstract>
         <kwd-group xml:lang="sl">
            <kwd>občutljivost na antibiotike</kwd>
            <kwd>otroci</kwd>
            <kwd>eradikacija</kwd>
            <kwd>bakterija Helicobacter pylori</kwd>
         </kwd-group>
         <kwd-group xml:lang="en">
            <kwd>antibiotic susceptibility</kwd>
            <kwd>children</kwd>
            <kwd>eradication</kwd>
            <kwd>Helicobacter pylori</kwd>
         </kwd-group>
      </article-meta>
   </front>
   <body>
      <sec id="s1" sec-type="Uvod">
         <label>1</label>
         <title>Uvod</title>
         <p>Z bakterijo <italic toggle="yes">Helicobacter pylori</italic> (<italic toggle="yes">H. pylori</italic>) se večinoma okužimo v otroštvu. Gre še vedno za najpogostejšo okužbo pri ljudeh, čeprav prevalenca okužbe v razvitem svetu vztrajno upada in je med 15 % in 20 % (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b2">2</xref>). Za razliko od odraslih bolnikov, pri katerih je kronična okužba s <italic toggle="yes">H. pylori</italic> pomemben povzročitelj raka želodca, gre pri otrocih večinoma za okužbo brez simptomov, ki je lahko povezana celo s koristnimi vplivi na imunski sistem okuženega otroka (<xref ref-type="bibr" rid="b3">3</xref>). Ob vsesplošni prepogosti uporabi antibiotikov in s tem visoki stopnji odpornosti proti antibiotikom pa je zdravljenje okužbe s <italic toggle="yes">H. pylori </italic>pri otrocih vse manj uspešno in je v zadnjih letih padlo pod želenih 90 % (<xref ref-type="bibr" rid="b4">4</xref>). Kljub številnim raziskavam znanstvenikom ni uspelo dokazati povezave med okužbo s <italic toggle="yes">H. pylori</italic> in kroničnimi bolečinami pri otrocih, ki nimajo dokazanih erozij ali razjed v področju sluznice zgornjih prebavil (<xref ref-type="bibr" rid="b5">5</xref>). Tudi zato se obravnava okužbe s <italic toggle="yes">H. pylori</italic> pri otrocih pomembno razlikuje glede na odrasle bolnike. Pri otrocih diagnosticiranje in zdravljenje nista vedno potrebni. V nadaljevanju prispevka razpravljam o pomembnejših zaključkih priporočil, ki smo jih izdali letos in veljajo samo za razviti svet, saj je prevalenca okužbe v nerazvitem svetu izrazito višja in v povprečju presega 80 % prebivalstva.</p>
      </sec>
      <sec id="s2"
           sec-type="Strategija »testiraj in zdravi« (»Test and treat«) pri otrocih ni smiselna">
         <label>2</label>
         <title>Strategija »testiraj in zdravi« (»Test and treat«) pri otrocih ni smiselna</title>
         <p>Pri odraslih bolnikih se za zdravljenje okužbe uporablja t. i. strategija »testiraj in zdravi«. Ob dolgotrajnih težavah v zgornjih prebavilih se glede na priporočila z neinvazivnim testom, bodisi antigenskim testom iz blata, bodisi z ureaznim dihalnim testom, lahko diagnosticira okužba in pri pozitivnem rezultatu predpiše eradikacijsko empirično zdravljenje. Pri otrocih tak način odkrivanja okužbe s <italic toggle="yes">H. pylori </italic>ni smiselen, saj kljub številnim raziskavam niso uspeli dokazati, da je kronična bolečina v trebuhu brez erozij ali razjed sluznice zgornjih prebavil povezana z okužbo s <italic toggle="yes">H. pylori </italic>(<xref ref-type="bibr" rid="b3">3</xref>). Ulkusna bolezen pri otrocih pa je zelo redka. Če z endoskopijo zgornjih prebavil dokažemo okužbo pri otroku, ki nima ulkusne bolezni, ne svetujemo vedno eradikacijskega zdravljenja. Razlogov za to je več. Raziskave kažejo, da najverjetneje po uspešni eradikaciji gastrointestinalni simptomi pri otroku ne bodo izzveneli. Možnost, da se bo pri otroku v naslednjih desetih letih razvila zaradi nezdravljene okužbe resnejša bolezen, kot sta razjeda dvanajstnika ali limfom MALT, je izredno majhna. Ob tem pa imajo okuženi otroci celo manj možnosti, da bodo zboleli za alergičnimi boleznimi in astmo (<xref ref-type="bibr" rid="b6">6</xref>). V času eradikacijskega zdravljenja se v polovici primerov razvijejo stranski učinki, kot so glavobol, driska, slabost, kovinski okus v ustih itd. Tudi če uspešno opravimo eradikacijo pri otroku, se moramo zavedati, da obstaja možnost za ponovno okužbo. Glede na raziskavo iz Nemčije, ki ima najverjetneje primerljive epidimiološke podatke kot Slovenija, je možnost ponovne okužbe 2,3 % letno (<xref ref-type="bibr" rid="b7">7</xref>). Če naključno odkrijemo bakterijo <italic toggle="yes">H. pylori,</italic> se v priporočilih svetuje, da otroku/staršem natančno razložimo razloge za oziroma razloge proti eradikacijskemu zdravljenju (izkoreninjenju bakterije) in se nato skupaj odločimo, ali bomo okužbo zdravili ali pa jo bomo samo spremljali.</p>
      </sec>
      <sec id="s3"
           sec-type="Indikacije za aktivno iskanje okužbe s H. pylori pri otrocih">
         <label>3</label>
         <title>Indikacije za aktivno iskanje okužbe s H. pylori pri otrocih</title>
         <p>Če ima otrok alarmne simptome ali znake v prebavilih, opravimo endoskopijo zgornjih prebavil za etiološko opredelitev težav. V primeru, da najdemo razjedo ali erozije želodca/dvanajstnika, moramo nujno odvzeti 2–4 vzorce bioptov želodčne sluznice za diagnosticiranje in kultiviranje <italic toggle="yes">H. pylori. </italic>Mesec dni po eradikacijskem zdravljenju je z neinvazivnimi testi potrebno preveriti uspešnost zdravljenja. Če izkoreninjenje bakterije ni uspelo, se bo ulkus sluznice želodca ali dvanajstnika najverjetneje ponovil (<xref ref-type="bibr" rid="b8">8</xref>). Če ima otrok kronične bolečine v trebuhu, ob tem pa nima alarmnih simptomov in znakov, diagnosticiranje bakterijske okužbe ni smiselno, saj gre najverjetneje za funkcionalne težave, ki ne bodo izzvenele, tudi če pri otroku bakterijsko okužbo uspešno ozdravimo.</p>
         <p>Okužbo s <italic toggle="yes">H. pylori</italic> pri otroku aktivno iščemo, če ima kronično imunsko trombocitopenično purpuro (cITP). Glede na objavljene raziskave se število trombocitov pri otroku poveča po uspešni eradikaciji okužbe z bakterijo <italic toggle="yes">H. </italic>
            <italic toggle="yes">pylori</italic> (<xref ref-type="bibr" rid="b9">9</xref>-<xref ref-type="bibr" rid="b11">11</xref>). Uspešnost zdravljenja je najverjetneje odvisna od prisotnosti virulenčnega gena <italic toggle="yes">cagA </italic>v genomu seva bakterije <italic toggle="yes">H. pylori</italic>. Molekularna zgradba beljakovine CagA je namreč zelo podobna trombocitnemu peptidu z molekulsko maso 55 kDa. Po uspešnem izkoreninjenju ne zaznamo več protiteles proti beljakovini CagA, hkrati pa izginejo tudi antitrombocitna protitelesa, zato se število trombocitov poviša. V Sloveniji je 61,2 % otrok okuženih s sevi <italic toggle="yes">H. pylori</italic>, ki nosijo v svojem zapisu tudi gen <italic toggle="yes">cagA</italic> (<xref ref-type="bibr" rid="b12">12</xref>,<xref ref-type="bibr" rid="b13">13</xref>). Pri otrocih s cITP se izjemoma lahko diagnosticira <italic toggle="yes">H. pylori</italic> tudi z neinvazivnimi metodami, kot sta urea dihalni test ali test za določanje antigena <italic toggle="yes">H. pylori</italic> v blatu. Zaradi trombocitopenije obstaja večja možnost zapleta – krvavitve – ob endoskopiji zgornjih prebavil z odvzemom vzorcev sluznice želodca za osamitev bakterije.</p>
         <p>Slabokrvnost zaradi pomanjkanja železa (v nadaljevanju <italic toggle="yes">slabokrvnost</italic>) je v otroštvu zelo pogosta zaradi visokih potreb po železu v obdobju odraščanja. Večinoma slabokrvnost<italic toggle="yes"> </italic>izzveni po ustreznem zdravljenju s pripravki železa. Slabokrvnost, ki se ne odziva na zdravljenje s pripravki železa, je lahko posledica izgub krvi zaradi ulkusne bolezni, ki jo povzroči <italic toggle="yes">H. pylori</italic> pri otroku (<xref ref-type="bibr" rid="b14">14</xref>). Bakterija železo, vnešeno s hrano, tudi porablja. V primeru, da gre pri otroku za slabokrvnost, ki se ne odziva na zdravljenje z železom, je zato smiselno opraviti endoskopsko diagnosticiranje okužbe z bakterijo <italic toggle="yes">H. pylori</italic> in jo pri pozitivnem izvidu tudi zdraviti.</p>
         <p>Zaenkrat še ni dovolj dokazov, da je kronična okužba s <italic toggle="yes">H. pylori</italic> lahko vzročno povezana z nizko rastjo. Nizka rast in bakterijska okužba sta povezani z nižjim ekonomskim standardom, zato je najverjetneje okužba pogostejša pri otrocih, ki so nizke rasti. Doslej je bilo opravljenih že veliko raziskav, ki pa so potekale večinoma v državah z nizkim ekonomskim standardom, zato zaenkrat nizka rast ni z dokazi podprt razlog za aktivno iskanje okužbe s <italic toggle="yes">H. </italic>
            <italic toggle="yes">pylori</italic> pri otroku (<xref ref-type="bibr" rid="b15">15</xref>).</p>
      </sec>
      <sec id="s4" sec-type="Diagnoza bakterijske okužbe">
         <label>4</label>
         <title>Diagnoza bakterijske okužbe</title>
         <p>Za razliko od odraslih bolnikov je potrebno za zanesljiv dokaz okužbe s <italic toggle="yes">H</italic>
            <italic toggle="yes">. pylori</italic> pri otrocih opraviti endoskopijo zgornjih prebavil z odvzemom vzorcev sluznice želodca. Za dokaz okužbe mora biti pozitivna bakterijska kultura ali histopatološki izvid s še enim testom, ki ga opravimo iz biopta želodčne sluznice: hitri ureazni test, molekularni test (dokaz bakterij s polimerazno verižno reakcijo). V primeru aktivne krvavitve iz prebavil je najbolj zanesljiv molekularni test (<xref ref-type="bibr" rid="b16">16</xref>). Med temi testi je 100-odstotno zanesljiva le kultivacija bakterije. Prevalenca okužbe pri otrocih je vse nižja, zato so ostali testi postali manj zanesljivi in ne zadošča več samo pozitiven histopatološki izvid. Poleg tega je hitri ureazni test manj zanesljiv pri otrocih, mlajših od petih let, najverjetneje zaradi manjšega števila bakterij na sluznici želodca. Uporaba seroloških testov z določanjem koncentracije IgA ali IgG bodisi v serumu, krvi, slini ali urinu pa se ne priporoča več niti v epidemiološke namene.</p>
         <p>Mesec dni ali več po zaključku eradikacijskega zdravljenja je potrebno preveriti uspešnost. Preverimo jo lahko z neinvazivnimi testi, kot sta ureazni dihalni test (13C-UBT) ali monoklonski test za določanje antigena <italic toggle="yes">H. pylori</italic> v blatu. Ostali neinvazivni testi so premalo zanesljivi. Zavedati se moramo tudi, da je pri otrocih, mlajših od šestih let, zaradi manjše prostornine pljuč in drugačne stopnje tvorjenja ogljikovega dioksida ureazni dihalni test lahko lažno pozitiven (<xref ref-type="bibr" rid="b17">17</xref>). Poleg tega majhni otroci težje sodelujejo pri dihalnem testu.</p>
      </sec>
      <sec id="s5" sec-type="Zdravljenje okužbe z bakterijo H. pylori">
         <label>5</label>
         <title>Zdravljenje okužbe z bakterijo H. pylori</title>
         <sec id="s5.1" sec-type="Prvo zdravljenje">
            <label>5.1</label>
            <title>Prvo zdravljenje</title>
            <p>Eradikacijsko zdravljenje predpišemo glede na antibiogram seva bakterije. Da izboljšamo občutljivost kultiviranja bakterije, je potrebno opraviti prenos vzorcev želodčne sluznice do laboratorija v ustreznem transportnem gojišču. Za izboljšanje občutljivosti metode z odkrivanjem mešanih okužb (z več kot enim sevom naenkrat) je priporočljivo, da odvzamemo vsaj dva vzorca, enega iz sluznice antruma in drugega iz sluznice korpusa želodca. Pri tem lahko oba vzorca za mikrobiološko analizo oddamo v istem transportnem gojišču.</p>
            <p>Kljub temu, da zdravimo ciljano – glede na antibiogram seva, je uspeh eradikacijskega zdravljenja še vedno manjši od želenih 90 % (<xref ref-type="bibr" rid="b18">18</xref>). V raziskavi iz Slovenije, ki smo jo objavili pred kratkim, je izkoreninjenje bakterije uspelo v 85,9 % (<xref ref-type="bibr" rid="b19">19</xref>). Najpomembnejši razlog za slabši uspeh eradikacije je bil v tem primeru slabši interes za zdravljenje (komplianca). Glede na raziskavo je potrebno prejeti vsaj 90 % predpisanih zdravil, da je lahko izkoreninjenje <italic toggle="yes">H. pylori</italic> uspešno (<xref ref-type="bibr" rid="b20">20</xref>). Razlog za slabši interes za zdravljenje je večje število različnih zdravil, 14-dnevno zdravljenje in pogost pojav stranskih učinkov. Pred pričetkom je otroku/staršem potrebno natančno razložiti shemo zdravljenja, pričakovane stranske učinke in predvsem, kako zelo pomembno za uspeh zdravljenja je, da prejme otrok vsa predpisana zdravila.</p>
            <p>Zdravljenje okužbe z bakterijo <italic toggle="yes">H. pylori</italic> pri otroku traja 14 dni. Odmerki zdravil so navedeni glede na otrokovo telesno težo (<xref ref-type="table" rid="table1">Tabela 1</xref>). Priporočila za prvo zdravljenje glede na občutljivost seva bakterije so:</p>
            <table-wrap position="anchor" id="table1" orientation="portrait">
               <label>Tabela 1:</label>
               <caption>
                  <p> Priporočeni odmerki zdravil glede na telesno težo otroka.</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Zdravilo</th>
                        <th align="center" rowspan="1" colspan="1">Telesna teža otroka</th>
                        <th align="center" rowspan="1" colspan="1">Zjutraj</th>
                        <th align="center" rowspan="1" colspan="1">Zvečer</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="3" colspan="1">ZPČ</td>
                        <td align="right" rowspan="1" colspan="1">15–24 kg</td>
                        <td align="right" rowspan="1" colspan="1">20 mg</td>
                        <td align="right" rowspan="1" colspan="1">20 mg</td>
                     </tr>
                     <tr>
                        <td align="right" rowspan="1" colspan="1">25–34 kg</td>
                        <td align="right" rowspan="1" colspan="1">30 mg</td>
                        <td align="right" rowspan="1" colspan="1">30 mg</td>
                     </tr>
                     <tr>
                        <td align="right" rowspan="1" colspan="1">&gt; 35 kg</td>
                        <td align="right" rowspan="1" colspan="1">40 mg</td>
                        <td align="right" rowspan="1" colspan="1">40 mg</td>
                     </tr>
                     <tr>
                        <td rowspan="3" colspan="1">AM</td>
                        <td align="right" rowspan="1" colspan="1">15–24 kg</td>
                        <td align="right" rowspan="1" colspan="1">500 mg (750 mg*)</td>
                        <td align="right" rowspan="1" colspan="1">500 mg (750 mg*)</td>
                     </tr>
                     <tr>
                        <td align="right" rowspan="1" colspan="1">25–34 kg</td>
                        <td align="right" rowspan="1" colspan="1">750 mg (1000 mg*)</td>
                        <td align="right" rowspan="1" colspan="1">750 mg (1000 mg*)</td>
                     </tr>
                     <tr>
                        <td align="right" rowspan="1" colspan="1">&gt; 35 kg</td>
                        <td align="right" rowspan="1" colspan="1">1000 mg (1500 mg*)</td>
                        <td align="right" rowspan="1" colspan="1">1000 mg (1500 mg*)</td>
                     </tr>
                     <tr>
                        <td rowspan="3" colspan="1">KL</td>
                        <td align="right" rowspan="1" colspan="1">15–24 kg</td>
                        <td align="right" rowspan="1" colspan="1">250 mg</td>
                        <td align="right" rowspan="1" colspan="1">250 mg</td>
                     </tr>
                     <tr>
                        <td align="right" rowspan="1" colspan="1">25–34 kg</td>
                        <td align="right" rowspan="1" colspan="1">500 mg</td>
                        <td align="right" rowspan="1" colspan="1">250 mg</td>
                     </tr>
                     <tr>
                        <td align="right" rowspan="1" colspan="1">&gt; 35 kg</td>
                        <td align="right" rowspan="1" colspan="1">500 mg</td>
                        <td align="right" rowspan="1" colspan="1">500 mg</td>
                     </tr>
                     <tr>
                        <td rowspan="3" colspan="1">ME</td>
                        <td align="right" rowspan="1" colspan="1">15–24 kg</td>
                        <td align="right" rowspan="1" colspan="1">250 mg</td>
                        <td align="right" rowspan="1" colspan="1">250 mg</td>
                     </tr>
                     <tr>
                        <td align="right" rowspan="1" colspan="1">25–34 kg</td>
                        <td align="right" rowspan="1" colspan="1">500 mg</td>
                        <td align="right" rowspan="1" colspan="1">250 mg</td>
                     </tr>
                     <tr>
                        <td align="right" rowspan="1" colspan="1">&gt; 35 kg</td>
                        <td align="right" rowspan="1" colspan="1">500 mg</td>
                        <td align="right" rowspan="1" colspan="1">500 mg</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>Legenda: ZPČ – zaviralec protonske črpalke, AM – amoksicilin, KL – klaritromicin, ME – metronidazol</p>
                  <p>* visoki odmerki AM</p>
               </table-wrap-foot>
            </table-wrap>
            <list>
               <list-item>
                  <label>1.</label>
                  <p>Zaviralec protonske črpalke (ZPČ), amoksicilin (AM), klaritromicin (KL) (sev ni rezistenten).</p>
               </list-item>
               <list-item>
                  <label>2.</label>
                  <p>ZPČ, AM, metronidazol (ME) (sev je rezistenten na KL).</p>
               </list-item>
               <list-item>
                  <label>3.</label>
                  <p>ZPČ, AM, KL (sev je rezistenten na ME).</p>
               </list-item>
               <list-item>
                  <label>4.</label>
                  <p>ZPČ, AM (visoki odmerki (<xref ref-type="table" rid="table1">Tabela 1</xref>), ME (sev je rezistenten na KL in ME).</p>
               </list-item>
               <list-item>
                  <label>5.</label>
                  <p>ZPČ, AM (visoki odmerki (<xref ref-type="table" rid="table1">Tabela 1</xref>)), ME (antibiograma seva nimamo).</p>
               </list-item>
            </list>
            <p>Uspeh je v največji meri odvisen od občutljivosti seva na antibiotike. V Sloveniji je odpornost na KL pri otrocih višja kot 20 %, medtem ko je pri odrasli populaciji nekoliko nižja. Odpornost na ME pa je višja od 20 % tako pri otrocih kot pri odraslih bolnikih (<xref ref-type="bibr" rid="b19">19</xref>,<xref ref-type="bibr" rid="b21">21</xref>,<xref ref-type="bibr" rid="b22">22</xref>). Če podatka o občutljivosti seva na antibiotike nimamo, potem v zdravljenje prve izbire ne vključimo KL zaradi visoke odpornosti pri otrocih v Sloveniji.</p>
            <p>Sekvenčno zdravljenje je eden možnih načinov zdravljenja okužbe z bakterijo <italic toggle="yes">H. pylori</italic> in je sestavljeno iz 10-dnevnega zdravljenja: z ZPČ in AM prvih pet dni, nato pa v naslednjih petih dneh kombinacija KL in ME. Desetdnevno sekvenčno zdravljenje se pri otrocih ni izkazalo za dovolj uspešno, če je bil sev odporen na KL. Lahko jo lahko uporabimo pri otrocih kot alternativo predlaganemu prvemu zdravljenju z ZPČ, AM in KL, pri katerem bakterijski sev ni odporen niti na ME in še posebno ne na KL.</p>
            <p>Eradikacijska shema, ki vključuje bizmutov pripravek (ZPČ, dva antibiotika), se lahko uporablja tudi pri otrocih in je na mestu kot alternativna terapija v primeru dvojno rezistentnih sevov ali v primeru, da seva nismo kultivirali.</p>
            <p>Rezultati večine metaanaliz o vlogi probiotikov kot možne dodatne terapije pri zdravljenju okužbe z bakterijo <italic toggle="yes">H.</italic>pylori pri odraslih kažejo na to, da je specifične seve probiotikov v zadostnih količinah smiselno dodajati običajnim eradikacijskim shemam (<xref ref-type="bibr" rid="b23">23</xref>). Vloga probiotikov, kot dodatne terapije, s katero izboljšamo delež uspešnega zdravljenja in zmanjšamo pogostost stranskih učinkov eradikacije pri otrocih, pa še ni jasna. Zaenkrat je bilo objavljenih premalo kakovostnih raziskav pri otrocih s specifičnimi probiotičnimi sevi bakterij, da bi probiotike lahko uvrstili v shemo za zdravljenje okužbe.</p>
         </sec>
         <sec id="s5.2"
              sec-type="Zdravljenje otroka, če prva terapija ni bila uspešna">
            <label>5.2</label>
            <title>Zdravljenje otroka, če prva terapija ni bila uspešna</title>
            <p>Uspešnost zdravljenja je potrebno vedno preveriti z ureaznim dihalnim testom ali monoklonskim testom za dokaz<italic toggle="yes"> </italic>bakterije<italic toggle="yes"> H. pylori </italic>antigena v blatu. Če je bilo zdravljenje neuspešno, eradikacijski protokol zamenjamo. Možnosti zdravljenja imamo manj kot pri odraslih bolnikih, kar je še dodaten razlog, zakaj je potrebno pravilno izbrati že prvo zdravljenje.</p>
            <p>Čas drugega zdravljenja traja prav tako 14 dni. Priporočila za drugo zdravljenje glede na občutljivost seva bakterije in glede na prvo eradikacijsko shemo so:</p>
            <p>1.ZPČ, AM, ME (sev ni bil rezistenten; prva terapija z ZPČ, AM, KL).</p>
            <list>
               <list-item>
                  <label>2.</label>
                  <p>ZPČ, AM, KL (sev ni bil rezistenten; prva terapija z ZPČ, AM, ME).</p>
               </list-item>
               <list-item>
                  <label>3.</label>
                  <p>ZPČ, AM (visoki odmerki (<xref ref-type="table" rid="table1">Tabela 1</xref>)), ME ali ponovi endoskopijo (antibiogram seva in zdravi glede na izvid) (sev ni bil rezistenten; prvo zdravljenje je bila sekvenčna terapija).</p>
               </list-item>
               <list-item>
                  <label>4.</label>
                  <p>ZPČ, AM (visoki odmerki (<xref ref-type="table" rid="table1">Tabela 1</xref>)), ME (sev je bil rezistenten na KL; prvo zdravljenje z ZPČ, AM, ME).</p>
               </list-item>
               <list-item>
                  <label>5.</label>
                  <p>ZPČ, AM (visoki odmerki (<xref ref-type="table" rid="table1">Tabela 1</xref>)),ME ali ponovi endoskopijo (antibiogram seva in zdravi glede na izvid) (sev je bil rezistenten na ME; prvo zdravljenje z ZPČ, AM, KL).</p>
               </list-item>
               <list-item>
                  <label>6.</label>
                  <p>ZPČ, AM (visoki odmerki (<xref ref-type="table" rid="table1">Tabela 1</xref>)),ME ali ponovi endoskopijo (antibiogram seva in zdravi glede na izvid) (antibiograma seva nismo imeli; prvo zdravljenje PPI, dva antibiotika).</p>
               </list-item>
            </list>
            <p>Vsekakor se mora druga terapevtska shema ob neuspešni prvi eradikaciji predpisati glede na občutljivost seva in prvi način zdravljenja. Raziskave pri odraslih kažejo na to, da je smiselno povišati odmerek ZPČ in ME (<xref ref-type="bibr" rid="b24">24</xref>). Pri otrocih smo že v osnovni shemi predvideli višji odmerke ZPČ, če jih primerjamo s priporočili iz leta 2011 (<xref ref-type="bibr" rid="b25">25</xref>). V raziskavi iz leta 2011 pa so zaključili, da je pri okužbi otrok s sevom, odpornimi proti ME in KL, smiselno uporabiti visoke odmerke ZPČ in AM, kar smo tudi upoštevali v predlaganih načinih zdravljenja (<xref ref-type="bibr" rid="b20">20</xref>).</p>
         </sec>
      </sec>
      <sec id="s6" sec-type="Zaključki">
         <label>6</label>
         <title>Zaključki</title>
         <p>Uspeh zdravljenja okužbe z bakterijo <italic toggle="yes">H. pylori</italic> je precej manjši od priporočenih 90 %, zato je potrebno antibiotike za 14-dnevno zdravljenje izbrati glede na občutljivost seva, s katerim je otrok okužen. Uporabiti moramo visoke odmerke ZPČ. Otroku/staršem je potrebno pred začetkom zdravljenja podrobno razložiti, kako pomembno je, da se pri otroku dosledno izvede predpisano zdravljenje in zaužijejo vsa predpisana zdravila. KL uporabimo le pri tistih bolnikih, ki dokazano niso okuženi s sevom, ki je odporen za KL. Če antibiotična odpornost seva bakterije ni znana in testa ne moremo opraviti, predpišemo trojno zdravljenje z ZPČ, ME in AM v visokem odmerku. Mesec dni po zaključku zdravljenja z ureaznim dihalnim testom ali testom za dokaz antigena bakterije <italic toggle="yes">H. pylori</italic> v blatu preverimo uspeh zdravljenja. Zdravljenje po neuspešnem prvem zdravljenju je težko izbrati, saj je pri otrocih izbor antibiotikov omejen, poleg tega pa je raziskav z zahtevnejšimi eradikacijskimi shemami pri otrocih malo.</p>
         <p>Rezultati novih prospektivnih raziskav pri otrocih, ki bi vključevali zdravljenje z bizmutovimi pripravki, terapijo s tremi antibiotiki in zdravljenje s specifičnimi probiotičnimi sevi, nam bi pomagali pri optimiziranju eradikacijskega zdravljenja drugega reda. V bližnji prihodnosti si veliko obetamo tudi od razvoja cepiva za zaščito pred okužbo z bakterijo <italic toggle="yes">H. pylori</italic> (<xref ref-type="bibr" rid="b26">26</xref>).</p>
      </sec>
   </body>
   <back>
      <ref-list>
         <ref id="b1">
            <label>1. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Jones</surname>
                     <given-names>NL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Koletzko</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Goodman</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bontems</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cadranel</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Casswall</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>ESPGHAN, NASPGHAN</collab>
                    </person-group>. 
                    <article-title>Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016)</article-title>. 
                    <source>J Pediatr Gastroenterol Nutr</source>. 
                    <year>2017</year>
                    <month>Jun</month>;
                    <volume>64</volume>(
                    <issue>6</issue>):
                    <fpage>991</fpage>–
                    <lpage>1003</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/MPG.0000000000001594</pub-id>
                    <pub-id pub-id-type="pmid">28541262</pub-id>
                    <issn>0277-2116</issn>
                </mixed-citation>
         </ref>
         <ref id="b2">
            <label>2. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Homan</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hojsak</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kolaček</surname>
                     <given-names>S</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Helicobacter pylori in pediatrics</article-title>. 
                    <source>Helicobacter</source>. 
                    <year>2012</year>
                    <month>Sep</month>;
                    <volume>17</volume>
                    <supplement>Suppl 1</supplement>:
                    <fpage>43</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1523-5378.2012.00982.x</pub-id>
                    <pub-id pub-id-type="pmid">22958155</pub-id>
                    <issn>1083-4389</issn>
                </mixed-citation>
         </ref>
         <ref id="b3">
            <label>3. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sierra</surname>
                     <given-names>MS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hastings</surname>
                     <given-names>EV</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Goodman</surname>
                     <given-names>KJ</given-names>
                  </name>
                    </person-group>. 
                    <article-title>What do we know about benefits of H. pylori treatment in childhood?</article-title>
                    <source>Gut Microbes</source>. 
                    <year>2013</year>
                    <month>Nov-Dec</month>;
                    <volume>4</volume>(
                    <issue>6</issue>):
                    <fpage>549</fpage>–
                    <lpage>67</lpage>. 
                    <pub-id pub-id-type="doi">10.4161/gmic.27000</pub-id>
                    <pub-id pub-id-type="pmid">24280768</pub-id>
                    <issn>1949-0976</issn>
                </mixed-citation>
         </ref>
         <ref id="b4">
            <label>4. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Graham</surname>
                     <given-names>DY</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fischbach</surname>
                     <given-names>L</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Helicobacter pylori treatment in the era of increasing antibiotic resistance</article-title>. 
                    <source>Gut</source>. 
                    <year>2010</year>
                    <month>Aug</month>;
                    <volume>59</volume>(
                    <issue>8</issue>):
                    <fpage>1143</fpage>–
                    <lpage>53</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/gut.2009.192757</pub-id>
                    <pub-id pub-id-type="pmid">20525969</pub-id>
                    <issn>0017-5749</issn>
                </mixed-citation>
         </ref>
         <ref id="b5">
            <label>5. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Spee</surname>
                     <given-names>LA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Madderom</surname>
                     <given-names>MB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pijpers</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>van Leeuwen</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Berger</surname>
                     <given-names>MY</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Association between helicobacter pylori and gastrointestinal symptoms in children</article-title>. 
                    <source>Pediatrics</source>. 
                    <year>2010</year>
                    <month>Mar</month>;
                    <volume>125</volume>(
                    <issue>3</issue>):
                    <fpage>e651</fpage>–
                    <lpage>69</lpage>. 
                    <pub-id pub-id-type="doi">10.1542/peds.2010-0941</pub-id>
                    <pub-id pub-id-type="pmid">20156901</pub-id>
                    <issn>0031-4005</issn>
                </mixed-citation>
         </ref>
         <ref id="b6">
            <label>6. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Holster</surname>
                     <given-names>IL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vila</surname>
                     <given-names>AM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Caudri</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>den Hoed</surname>
                     <given-names>CM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Perez-Perez</surname>
                     <given-names>GI</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Blaser</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The impact of Helicobacter pylori on atopic disorders in childhood</article-title>. 
                    <source>Helicobacter</source>. 
                    <year>2012</year>
                    <month>Jun</month>;
                    <volume>17</volume>(
                    <issue>3</issue>):
                    <fpage>232</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1523-5378.2012.00934.x</pub-id>
                    <pub-id pub-id-type="pmid">22515362</pub-id>
                    <issn>1083-4389</issn>
                </mixed-citation>
         </ref>
         <ref id="b7">
            <label>7. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Feydt-Schmidt</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kindermann</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Konstantopoulos</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Demmelmair</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ballauff</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Findeisen</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Reinfection rate in children after successful Helicobacter pylori eradication</article-title>. 
                    <source>Eur J Gastroenterol Hepatol</source>. 
                    <year>2002</year>
                    <month>Oct</month>;
                    <volume>14</volume>(
                    <issue>10</issue>):
                    <fpage>1119</fpage>–
                    <lpage>23</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/00042737-200210000-00013</pub-id>
                    <pub-id pub-id-type="pmid">12362103</pub-id>
                    <issn>0954-691X</issn>
                </mixed-citation>
         </ref>
         <ref id="b8">
            <label>8. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Bontems</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kalach</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vanderpas</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Iwanczak</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Casswall</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Koletzko</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Helicobacter pylori Infection in European children with gastro-duodenal ulcers and erosions</article-title>. 
                    <source>Pediatr Infect Dis J</source>. 
                    <year>2013</year>
                    <month>Dec</month>;
                    <volume>32</volume>(
                    <issue>12</issue>):
                    <fpage>1324</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/INF.0000000000000005</pub-id>
                    <pub-id pub-id-type="pmid">24569306</pub-id>
                    <issn>0891-3668</issn>
                </mixed-citation>
         </ref>
         <ref id="b9">
            <label>9. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Brito</surname>
                     <given-names>HS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Braga</surname>
                     <given-names>JA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Loggetto</surname>
                     <given-names>SR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Machado</surname>
                     <given-names>RS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Granato</surname>
                     <given-names>CF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kawakami</surname>
                     <given-names>E</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Helicobacter pylori infection &amp; immune thrombocytopenic purpura in children and adolescents: A randomized controlled trial</article-title>. 
                    <source>Platelets</source>. 
                    <year>2015</year>;
                    <volume>26</volume>(
                    <issue>4</issue>):
                    <fpage>336</fpage>–
                    <lpage>41</lpage>. 
                    <pub-id pub-id-type="doi">10.3109/09537104.2014.911836</pub-id>
                    <pub-id pub-id-type="pmid">24832381</pub-id>
                    <issn>0953-7104</issn>
                </mixed-citation>
         </ref>
         <ref id="b10">
            <label>10. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Russo</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Miraglia</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Branciforte</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Matarese</surname>
                     <given-names>SM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zecca</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bisogno</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>AIEOP-ITP Study Group</collab>
                    </person-group>. 
                    <article-title>Effect of eradication of Helicobacter pylori in children with chronic immune thrombocytopenia: a prospective, controlled, multicenter study</article-title>. 
                    <source>Pediatr Blood Cancer</source>. 
                    <year>2011</year>
                    <month>Feb</month>;
                    <volume>56</volume>(
                    <issue>2</issue>):
                    <fpage>273</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/pbc.22770</pub-id>
                    <pub-id pub-id-type="pmid">20830773</pub-id>
                    <issn>1545-5009</issn>
                </mixed-citation>
         </ref>
         <ref id="b11">
            <label>11. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ferrara</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Capozzi</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Russo</surname>
                     <given-names>R</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Effect of Helicobacter pylori eradication on platelet count in children with chronic idiopathic thrombocytopenic purpura</article-title>. 
                    <source>Hematology</source>. 
                    <year>2009</year>
                    <month>Oct</month>;
                    <volume>14</volume>(
                    <issue>5</issue>):
                    <fpage>282</fpage>–
                    <lpage>5</lpage>. 
                    <pub-id pub-id-type="doi">10.1179/102453309X12473408860181</pub-id>
                    <pub-id pub-id-type="pmid">19843384</pub-id>
                    <issn>1607-8454</issn>
                </mixed-citation>
         </ref>
         <ref id="b12">
            <label>12. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Homan</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Luzar</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kocjan</surname>
                     <given-names>BJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Orel</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mocilnik</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Shrestha</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Prevalence and clinical relevance of cagA, vacA, and iceA genotypes of Helicobacter pylori isolated from Slovenian children</article-title>. 
                    <source>J Pediatr Gastroenterol Nutr</source>. 
                    <year>2009</year>
                    <month>Sep</month>;
                    <volume>49</volume>(
                    <issue>3</issue>):
                    <fpage>289</fpage>–
                    <lpage>96</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/MPG.0b013e31818f09f2</pub-id>
                    <pub-id pub-id-type="pmid">19525870</pub-id>
                    <issn>0277-2116</issn>
                </mixed-citation>
         </ref>
         <ref id="b13">
            <label>13. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Homan</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Šterbenc</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kocjan</surname>
                     <given-names>BJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Luzar</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zidar</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Orel</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Prevalence of the Helicobacter pylori babA2 gene and correlation with the degree of gastritis in infected Slovenian children</article-title>. 
                    <source>Antonie van Leeuwenhoek</source>. 
                    <year>2014</year>
                    <month>Oct</month>;
                    <volume>106</volume>(
                    <issue>4</issue>):
                    <fpage>637</fpage>–
                    <lpage>45</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s10482-014-0234-0</pub-id>
                    <pub-id pub-id-type="pmid">25055876</pub-id>
                    <issn>0003-6072</issn>
                </mixed-citation>
         </ref>
         <ref id="b14">
            <label>14. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Thankachan</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Muthayya</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sierksma</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Eilander</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Thomas</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Duchateau</surname>
                     <given-names>GS</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Helicobacter pylori infection does not influence the efficacy of iron and vitamin B(12) fortification in marginally nourished Indian children</article-title>. 
                    <source>Eur J Clin Nutr</source>. 
                    <year>2010</year>
                    <month>Oct</month>;
                    <volume>64</volume>(
                    <issue>10</issue>):
                    <fpage>1101</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/ejcn.2010.126</pub-id>
                    <pub-id pub-id-type="pmid">20683455</pub-id>
                    <issn>0954-3007</issn>
                </mixed-citation>
         </ref>
         <ref id="b15">
            <label>15. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Goodman</surname>
                     <given-names>KJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Correa</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mera</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yepez</surname>
                     <given-names>MC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cerón</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Campo</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Effect of Helicobacter pylori infection on growth velocity of school-age Andean children</article-title>. 
                    <source>Epidemiology</source>. 
                    <year>2011</year>
                    <month>Jan</month>;
                    <volume>22</volume>(
                    <issue>1</issue>):
                    <fpage>118</fpage>–
                    <lpage>26</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/EDE.0b013e3181fe7e31</pub-id>
                    <pub-id pub-id-type="pmid">21068668</pub-id>
                    <issn>1044-3983</issn>
                </mixed-citation>
         </ref>
         <ref id="b16">
            <label>16. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Rimbara</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sasatsu</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Graham</surname>
                     <given-names>DY</given-names>
                  </name>
                    </person-group>. 
                    <article-title>PCR detection of Helicobacter pylori in clinical samples</article-title>. 
                    <source>Methods Mol Biol</source>. 
                    <year>2013</year>;
                    <volume>943</volume>:
                    <fpage>279</fpage>–
                    <lpage>87</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/978-1-60327-353-4_19</pub-id>
                    <pub-id pub-id-type="pmid">23104297</pub-id>
                    <issn>1064-3745</issn>
                </mixed-citation>
         </ref>
         <ref id="b17">
            <label>17. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Leal</surname>
                     <given-names>YA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Flores</surname>
                     <given-names>LL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fuentes-Pananá</surname>
                     <given-names>EM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cedillo-Rivera</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Torres</surname>
                     <given-names>J</given-names>
                  </name>
                    </person-group>. 
                    <article-title>13C-urea breath test for the diagnosis of Helicobacter pylori infection in children: a systematic review and meta-analysis</article-title>. 
                    <source>Helicobacter</source>. 
                    <year>2011</year>
                    <month>Aug</month>;
                    <volume>16</volume>(
                    <issue>4</issue>):
                    <fpage>327</fpage>–
                    <lpage>37</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1523-5378.2011.00863.x</pub-id>
                    <pub-id pub-id-type="pmid">21762274</pub-id>
                    <issn>1083-4389</issn>
                </mixed-citation>
         </ref>
         <ref id="b18">
            <label>18. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Graham</surname>
                     <given-names>DY</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lee</surname>
                     <given-names>YC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wu</surname>
                     <given-names>MS</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence</article-title>. 
                    <source>Clin Gastroenterol Hepatol</source>. 
                    <year>2014</year>;
                    <volume>12</volume>:(
                    <issue>2</issue>):
                    <fpage>177</fpage>-
                    <lpage>86.e3</lpage>
                    <issn>1542-3565</issn>
                </mixed-citation>
         </ref>
         <ref id="b19">
            <label>19. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Butenko</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jeverica</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Orel</surname>
                     <given-names>S</given-names>
                  </name>,
                        <name name-style="western">
                     <surname>Homan</surname>
                     <given-names>M</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Antibacterial resistance and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian childrene</article-title>. 
                    <source>Helicobacter</source>. 
                    <year>2017</year>;
                    <volume>22</volume>:(
                    <issue>5</issue>):
                    <fpage>e12400</fpage>
                    <pub-id pub-id-type="doi">10.1111/hel.12400</pub-id>
                    <pub-id pub-id-type="pmid">28653787</pub-id>
                    <issn>1083-4389</issn>
                </mixed-citation>
         </ref>
         <ref id="b20">
            <label>20. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Schwarzer</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bontems</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Urruzuno</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kalach</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Iwanczak</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Roma-Giannikou</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Sequential Therapy for Helicobacter pylori Infection in Treatment-naïve Children</article-title>. 
                    <source>Helicobacter</source>. 
                    <year>2016</year>
                    <month>Apr</month>;
                    <volume>21</volume>(
                    <issue>2</issue>):
                    <fpage>106</fpage>–
                    <lpage>13</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/hel.12240</pub-id>
                    <pub-id pub-id-type="pmid">26123402</pub-id>
                    <issn>1083-4389</issn>
                </mixed-citation>
         </ref>
         <ref id="b21">
            <label>21. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Tepeš</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vujasinović</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Šeruga</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Stefanovič</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Forte</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jeverica</surname>
                     <given-names>S</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication</article-title>. 
                    <source>Eur J Gastroenterol Hepatol</source>. 
                    <year>2016</year>
                    <month>Jun</month>;
                    <volume>28</volume>(
                    <issue>6</issue>):
                    <fpage>676</fpage>–
                    <lpage>83</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/MEG.0000000000000590</pub-id>
                    <pub-id pub-id-type="pmid">26862930</pub-id>
                    <issn>0954-691X</issn>
                </mixed-citation>
         </ref>
         <ref id="b22">
            <label>22. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Jeverica</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tepeš</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ihan</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Skvarč</surname>
                     <given-names>M</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Primarna odpornost bakterije Helicobacter pylori</article-title>. 
                    <source>Zdrav Vestn</source>. 
                    <year>2010</year>;
                    <volume>79</volume>:(
                    <issue>1</issue>):
                    <fpage>25</fpage>–
                    <lpage>30</lpage>.
                    <issn>0350-0063</issn>
                </mixed-citation>
         </ref>
         <ref id="b23">
            <label>23. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Zhu</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chen</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zheng</surname>
                     <given-names>YY</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zhang</surname>
                     <given-names>HW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wang</surname>
                     <given-names>JS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Xia</surname>
                     <given-names>YJ</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy</article-title>. 
                    <source>World J Gastroenterol</source>. 
                    <year>2014</year>
                    <month>Dec</month>;
                    <volume>20</volume>(
                    <issue>47</issue>):
                    <fpage>18013</fpage>–
                    <lpage>21</lpage>. 
                    <pub-id pub-id-type="doi">10.3748/wjg.v20.i47.18013</pub-id>
                    <pub-id pub-id-type="pmid">25548501</pub-id>
                    <issn>1007-9327</issn>
                </mixed-citation>
         </ref>
         <ref id="b24">
            <label>24. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Molina-Infante</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lucendo</surname>
                     <given-names>AJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Angueira</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rodriguez-Tellez</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Perez-Aisa</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Balboa</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>European Registry on H. pylori management (Hp‐EuReg)</collab>
                    </person-group>. 
                    <article-title>Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study</article-title>. 
                    <source>Aliment Pharmacol Ther</source>. 
                    <year>2015</year>
                    <month>Mar</month>;
                    <volume>41</volume>(
                    <issue>6</issue>):
                    <fpage>581</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/apt.13069</pub-id>
                    <pub-id pub-id-type="pmid">25776067</pub-id>
                    <issn>0269-2813</issn>
                </mixed-citation>
         </ref>
         <ref id="b25">
            <label>25. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Koletzko</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jones</surname>
                     <given-names>NL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Goodman</surname>
                     <given-names>KJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gold</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rowland</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cadranel</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>H pylori Working Groups of ESPGHAN and NASPGHAN</collab>
                    </person-group>. 
                    <article-title>Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children</article-title>. 
                    <source>J Pediatr Gastroenterol Nutr</source>. 
                    <year>2011</year>
                    <month>Aug</month>;
                    <volume>53</volume>(
                    <issue>2</issue>):
                    <fpage>230</fpage>–
                    <lpage>43</lpage>.
                    <pub-id pub-id-type="pmid">21558964</pub-id>
                    <issn>1536-4801</issn>
                </mixed-citation>
         </ref>
         <ref id="b26">
            <label>26. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Schwarzer</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bontems</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Urruzuno</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kalach</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Iwanczak</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Roma-Giannikou</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Sequential Therapy for Helicobacter pylori Infection in Treatment-naïve Children</article-title>. 
                    <source>Helicobacter</source>. 
                    <year>2016</year>
                    <month>Apr</month>;
                    <volume>21</volume>(
                    <issue>2</issue>):
                    <fpage>106</fpage>–
                    <lpage>13</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/hel.12240</pub-id>
                    <pub-id pub-id-type="pmid">26123402</pub-id>
                    <issn>1083-4389</issn>
                </mixed-citation>
         </ref>
         <ref id="b27">
            <label>27. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Zeng</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mao</surname>
                     <given-names>XH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Li</surname>
                     <given-names>JX</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tong</surname>
                     <given-names>WD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wang</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zhang</surname>
                     <given-names>YJ</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial</article-title>. 
                    <source>Lancet</source>. 
                    <year>2015</year>
                    <month>Oct</month>;
                    <volume>386</volume>(
                    <issue>10002</issue>):
                    <fpage>1457</fpage>–
                    <lpage>64</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S0140-6736(15)60310-5</pub-id>
                    <pub-id pub-id-type="pmid">26142048</pub-id>
                    <issn>0140-6736</issn>
                </mixed-citation>
         </ref>
      </ref-list>
   </back>
   <sub-article id="article-en" xml:lang="en" article-type="other">
      <front-stub>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Metabolic and hormonal disorders</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Professional article</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="en">
               <subject>Metabolic and hormonal disorders</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="en">Approach to Helicobacter pylori infection in paediatric population</article-title>
            <alt-title alt-title-type="running-head" xml:lang="en">Approach to Helicobacter pylori infection in paediatric population</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Homan</surname>
                  <given-names>Matjaž</given-names>
               </name>
               <xref ref-type="aff" rid="en-aff1">1</xref>
               <xref ref-type="corresp" rid="en-corr"/>
            </contrib>
         </contrib-group>
         <aff id="en-aff1" xml:lang="en">
            <label>1</label>
            <institution>Unit of Gastroenterology and Hepatology, Division of Paediatrics, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
         </aff>
         <abstract xml:lang="en">
            <title>Abstract</title>
            <p>Prevalence of <italic toggle="yes">Helicobacter pylori</italic> infection has decreased significantly in recent years, especially in the developed world where it dropped below 20 %. In the majority of cases in children, <italic toggle="yes">Helicobacter pylori</italic> causes asymptomatic chronic gastritis. Systematic reviews and meta-analysis showed that recurrent abdominal pains in children are not associated with bacterial infection. Therefore “test and treat” strategy is not recommended in paediatric population. Eradication therapy should be prescribed according to antimicrobial sensitivity of the bacterial strain obtained during endoscopy. The article summarizes recent recommendations and guidelines of the joint North American and European Society of Paediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN, ESPGHAN) published this year and based on the systemic review of published studies from the field.</p>
         </abstract>
      </front-stub>
      <body>
         <sec id="en-s1" sec-type="Introduction">
            <label>1</label>
            <title>Introduction</title>
            <p>
               <italic toggle="yes">Helicobacter pylori </italic>(<italic toggle="yes">H.pylori) </italic>infection most frequently occurs in childhood. It remains one of the most common infections in man although in developed countries its prevalence has been decreasing steadily and is currently 15–20 % (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b2">2</xref>). Unlike in adults in whom <italic toggle="yes">H. pylori </italic>infection is an important cause of gastric cancer, in children the infection is mostly asymptomatic and may even have beneficial effects on their immune system (<xref ref-type="bibr" rid="en-b3">3</xref>). Because of overuse of antibiotics and the associated widespread antibiotic resistance, the efficacy of <italic toggle="yes">H. pylori </italic>infection treatment in children has declined below the acceptable level of 90 % (<xref ref-type="bibr" rid="en-b4">4</xref>). Extensive research on the subject failed to confirm the association between <italic toggle="yes">H</italic>
               <italic toggle="yes">. pylori </italic>infection and chronic gastric pain in children without endoscopic evidence of upper gastrointestinal erosions or ulcers (<xref ref-type="bibr" rid="en-b5">5</xref>). Therefore treatment of <italic toggle="yes">H. pylori </italic>infection in children differs significantly from that in adults. In the paediatric population the diagnostic evaluation and treatment are not always necessary. The paper deals with relevant conclusions of the 2018 guidelines for <italic toggle="yes">H. pylori</italic> management in the developed world. The prevalence of infection in developing countries is significantly higher: it affects more than 80 % of the population on average.</p>
         </sec>
         <sec id="en-s2"
              sec-type="»Test and treat » strategy in children is not sensible">
            <label>2</label>
            <title>»Test and treat » strategy in children is not sensible</title>
            <p>The so-called »test and treat« approach is used in adults infected with <italic toggle="yes">H. pylori. </italic>Individuals with chronic upper gastrointestinal symptoms are assessed by a non-invasive test for detection of<italic toggle="yes"> H. pylori</italic>, either by a stool antigen test or urea breath test. Patients with positive test results are started on empirical eradication therapy. However, there is no evidence regarding health benefits to children from testing for <italic toggle="yes">H. pylori.</italic> Extensive research on the subject has provided no evidence to confirm the association between chronic abdominal pain and <italic toggle="yes">H. pylori</italic> infection in children without evidence of upper gastrointestinal ulcerations and erosions (<xref ref-type="bibr" rid="en-b3">3</xref>). Peptic ulcer disease in children is very rare. Eradication therapy is not invariably recommended in children without ulcer disease who have endoscopically diagnosed upper gastrointestinal <italic toggle="yes">H. pylori </italic>infection. There are several reasons for this strategy: a)according to the studies conducted hithero, successful <italic toggle="yes">H. pylori</italic> eradication will most probably provide no improvement of gastrointestinal symptoms; b) it is most unlikely that within the ensuing ten year a child not treated for <italic toggle="yes">H. pylori</italic> infection will develop a serious disease, such as duodenal ulcer od MALT lymphoma; and c) children infected with <italic toggle="yes">H. pylori</italic> are less likely to develop allergic diseases or asthma (<xref ref-type="bibr" rid="en-b6">6</xref>). During eradication treatment, half of the patients complain of adverse side-effects, such as headache, diarrhoea, nausea and metallic taste in the mouth. It should be borne in mind that infection may recur despite successful eradication therapy. According to the results of the German study based on the epidemiological data comparable to those for Slovenia, the probable reinfection rate is 2.3 % per year (<xref ref-type="bibr" rid="en-b7">7</xref>). If <italic toggle="yes">H. pylori</italic> is detected by chance, the reasons against eradication treatment are explained to the infected child or the child‘s parents and the decision to either treat or only monitor the infection is made together with them.</p>
         </sec>
         <sec id="en-s3"
              sec-type="Indications for active testing for H. pylori in children">
            <label>3</label>
            <title>Indications for active testing for H. pylori in children</title>
            <p>A child with alarm upper gastrointestinal signs or symptoms should have upper gastrointestinal endoscopy to determine the causes of the health problem. If gastric/duodenal ulceration or erosion is found, it is imperative to collect two to four gastric mucosa biopsy samples for diagnosis and culture of <italic toggle="yes">H. pylori</italic>. Efficacy of eradication therapy should be assessed at one month after the completion of treatment using non-invasive tests. Gastric or duodenal ulcer is very likely to recur if <italic toggle="yes">H. pylori</italic>
               <italic toggle="yes"> </italic>has not been successfully eradicated (<xref ref-type="bibr" rid="en-b8">8</xref>). Testing for bacterial infection is not required in children with chronic abdominal pain without alarm signs and symptoms. This pain is most probably functional and will not be relieved by successful eradication of <italic toggle="yes">H</italic>
               <italic toggle="yes">. pylori.</italic>
            </p>
            <p>Active testing for H. pylori is necessary in a child presenting with chronic immune thrombocytopenic purpura (cITP). As demonstrated by the studies published hitherto, platelet count tends to improve once <italic toggle="yes">H. pylori </italic>has been succcessfully eradicated (<xref ref-type="bibr" rid="en-b9">9</xref>-<xref ref-type="bibr" rid="en-b11">11</xref>). The efficacy of therapy seems to depend on the presence of virulence gene cagA in the genome of <italic toggle="yes">H. pylori </italic>strains. Molecular structure of cagA is very similar to that of platelet peptide with a molecular mass of 55 kDa. After successful bacteria eradication, antibodies to cagA protein are no longer detectable; antiplatelet antibodies disappear, and as a result, platelet count rises. In Slovenia, 61.2 % of children are infected with <italic toggle="yes">H. pylori</italic> strains with cagA in their genome (<xref ref-type="bibr" rid="en-b12">12</xref>,<xref ref-type="bibr" rid="en-b13">13</xref>). Only exceptionally, non-invasive tests, such as stool antigen test or urea breath test, can be used for the diagnosis of <italic toggle="yes">H.pylori</italic>
               <italic toggle="yes"> </italic>infection in children with cITP.Thrombocytopenia increases the risk of complications (bleeding) during upper gastrointestinal endoscopy and biopsy sample collection for bacterial culture.</p>
            <p>Iron-deficiency anaemia is a frequent childhood disorder due to high iron requirements during growth periods, and is usually well managed by iron replacement therapy. Anaemia that is not responding to iron supplementation may be due to blood loss associated with<italic toggle="yes"> H.pylori</italic>-caused ulcer disease (<xref ref-type="bibr" rid="en-b14">14</xref>). <italic toggle="yes">H.pylori </italic>is known to feed on dietary iron. If anaemia fails to improve despite iron replacement therapy, it is sensible to perform endoscopy and institute appropriate treatment if <italic toggle="yes">H</italic>
               <italic toggle="yes">.pylori</italic> infection is diagnosed.</p>
            <p>There is no sufficient evidence to confirm that chronic <italic toggle="yes">H.pylori</italic> infection impairs growth. Since short stature and bacterial infection are associated with low socioeconomic status, infection is more likely to occur in children with short stature. Numerous studies, most of them conducted in low-income countries, failed to confirm that short stature in childhood is an evidence-based argument for initiating testing fo<italic toggle="yes">r H.</italic>
               <italic toggle="yes">pylori</italic> infection (<xref ref-type="bibr" rid="en-b15">15</xref>).</p>
         </sec>
         <sec id="en-s4" sec-type="Diagnosis of bacterial infection">
            <label>4</label>
            <title>Diagnosis of bacterial infection</title>
            <p>Unlike in adult patients, in children definitive diagnosis of <italic toggle="yes">H.pylori</italic> infection should always be based on the results of upper gastrointestinal endoscopy and gastric mucosal biopsy. The diagnosis should be ultimately confirmed by another test of gastric mucosal biopsy specimen, i.e. fast urease test or molecular test (polymerase chain reaction).Molecular test is the most reliable test for detecting active bleeding in the digestive tract (<xref ref-type="bibr" rid="en-b16">16</xref>). Identification of <italic toggle="yes">H.pylori</italic> from bacterial culture is the only method with a 100 % reliability. Prevalence of<italic toggle="yes"> H.pylori </italic>infection in children has been decreasing, therefore all other tests have become less reliable. The diagnosis should not be based on a positive histopathological test alone. In children younger than five years, the reliability of fast urease test is lower, most probably because of small number of bacteria present on the gastric mucosa. Serological tests for determination of IgA or IgG in the serum, blood, saliva or urine are no longer recommended, not even in epidemiology.</p>
            <p>The effectiveness of eradication therapy should be determined one month after the completion of treatment. Non-invasive tests, such as urease breath test (<sup>13</sup>C-UBT) or stool antigen test are employed. Other non-invasive methods have been shown to have insufficent reliability. In children aged less than six years, urea breath test may yield false positive results because of the child‘s small lung volume and different level of carbon dioxide production (<xref ref-type="bibr" rid="en-b17">17</xref>). Moreover, it is difficult to get small children to cooperate in testing.</p>
         </sec>
         <sec id="en-s5" sec-type="Treatment of H.pylori infection">
            <label>5</label>
            <title>Treatment of H.pylori infection</title>
            <sec id="en-s5.1" sec-type="First-line treatment">
               <label>5.1</label>
               <title>First-line treatment</title>
               <p>Eradication therapy is based on the determination of antibiotic sensitivity of bacterial strains. In order to improve bacterial culture sensitivity, a special transport medium is used for transporting gastric mucosal samples to the microbiology laboratory. Sensitivity of the method for detecting mixed-strain infection is improved by taking at least two mucosal specimens, one from the gastric antrum and another from the gastric body. One transport medium can be used for transporting both specimens to the microbiology laboratory for analysis.</p>
               <p>Despite the use of targeted antibiotic therapy – based on antibiotic susceptibility testing – the eradication treatment success rate remains below the acceptable level of 90 % (<xref ref-type="bibr" rid="en-b18">18</xref>). In the Slovenian study published in 2017, the rate of bacterial eradication was 85.9 % (<xref ref-type="bibr" rid="en-b19">19</xref>). Poor treatment compliance was identified as the main reason for low success rate of eradication therapy. The results of the study indicate that at least 90 % of the prescribed medications should be taken for <italic toggle="yes">H.pylori</italic>
                  <italic toggle="yes"> </italic>eradication to be successful (<xref ref-type="bibr" rid="en-b20">20</xref>). Poor treatment adherence is attributable to a large number of drugs prescribed, a 14-day regimen and high incidence of side effects. Prior to treatment, the child or the child‘s parents should be given a clear explanation of the treatment plan and possible side effects, and the importance of full adherence to the prescribed medications should be stressed.</p>
               <p>Children with <italic toggle="yes">H.pylori</italic> infection are treated for 14 days. Body-weight-tailored drug doses are indicated in <xref ref-type="table" rid="en-table1">Table 1</xref>.</p>
               <table-wrap position="anchor" id="en-table1" orientation="portrait">
                  <label>Table 1:</label>
                  <caption>
                     <p> Recommended body-weigh-tailored doses</p>
                  </caption>
                  <table>
                     <colgroup span="1">
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                     </colgroup>
                     <thead>
                        <tr>
                           <th rowspan="1" colspan="1">Medication</th>
                           <th align="center" rowspan="1" colspan="1">Body weight</th>
                           <th align="center" rowspan="1" colspan="1">Morning</th>
                           <th align="center" rowspan="1" colspan="1">Evening</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td rowspan="3" colspan="1">PPI</td>
                           <td align="right" rowspan="1" colspan="1">15 to 24 kg</td>
                           <td align="right" rowspan="1" colspan="1">20 mg</td>
                           <td align="right" rowspan="1" colspan="1">20 mg</td>
                        </tr>
                        <tr>
                           <td align="right" rowspan="1" colspan="1">25 to 34 kg</td>
                           <td align="right" rowspan="1" colspan="1">30 mg</td>
                           <td align="right" rowspan="1" colspan="1">30 mg</td>
                        </tr>
                        <tr>
                           <td align="right" rowspan="1" colspan="1">&gt; 35 kg</td>
                           <td align="right" rowspan="1" colspan="1">40 mg</td>
                           <td align="right" rowspan="1" colspan="1">40 mg</td>
                        </tr>
                        <tr>
                           <td rowspan="3" colspan="1">AM</td>
                           <td align="right" rowspan="1" colspan="1">15 to 24 kg</td>
                           <td align="right" rowspan="1" colspan="1">500 mg (750 mg*)</td>
                           <td align="right" rowspan="1" colspan="1">500 mg (750 mg*)</td>
                        </tr>
                        <tr>
                           <td align="right" rowspan="1" colspan="1">25 to 34 kg</td>
                           <td align="right" rowspan="1" colspan="1">750 mg (1000 mg*)</td>
                           <td align="right" rowspan="1" colspan="1">750 mg (1000 mg*)</td>
                        </tr>
                        <tr>
                           <td align="right" rowspan="1" colspan="1">&gt; 35 kg</td>
                           <td align="right" rowspan="1" colspan="1">1000 mg (1500 mg*)</td>
                           <td align="right" rowspan="1" colspan="1">1000 mg (1500 mg*)</td>
                        </tr>
                        <tr>
                           <td rowspan="3" colspan="1">CL</td>
                           <td align="right" rowspan="1" colspan="1">15 to 24 kg</td>
                           <td align="right" rowspan="1" colspan="1">250 mg</td>
                           <td align="right" rowspan="1" colspan="1">250 mg</td>
                        </tr>
                        <tr>
                           <td align="right" rowspan="1" colspan="1">25 to 34 kg</td>
                           <td align="right" rowspan="1" colspan="1">500 mg</td>
                           <td align="right" rowspan="1" colspan="1">250 mg</td>
                        </tr>
                        <tr>
                           <td align="right" rowspan="1" colspan="1">&gt; 35 kg</td>
                           <td align="right" rowspan="1" colspan="1">500 mg</td>
                           <td align="right" rowspan="1" colspan="1">500 mg</td>
                        </tr>
                        <tr>
                           <td rowspan="3" colspan="1">ME</td>
                           <td align="right" rowspan="1" colspan="1">15 to 24 kg</td>
                           <td align="right" rowspan="1" colspan="1">250 mg</td>
                           <td align="right" rowspan="1" colspan="1">250 mg</td>
                        </tr>
                        <tr>
                           <td align="right" rowspan="1" colspan="1">25 to 34 kg</td>
                           <td align="right" rowspan="1" colspan="1">500 mg</td>
                           <td align="right" rowspan="1" colspan="1">250 mg</td>
                        </tr>
                        <tr>
                           <td align="right" rowspan="1" colspan="1">&gt; 35 kg</td>
                           <td align="right" rowspan="1" colspan="1">500 mg</td>
                           <td align="right" rowspan="1" colspan="1">500 mg</td>
                        </tr>
                     </tbody>
                  </table>
                  <table-wrap-foot>
                     <p>PPI –proton pump inhibitor, AM – amoxycillin, CL – clarithromycin, ME – metronidazole</p>
                     <p>* high-dose AM</p>
                  </table-wrap-foot>
               </table-wrap>
               <p>Guidelines for the first-line treatment of <italic toggle="yes">H.pylori </italic>based on antibiotic sensitivity testing.</p>
               <list>
                  <list-item>
                     <label>1.</label>
                     <p>Proton pump inhibitor (PPI), amoxycillin (AM), clarithromycin (CL) (non-resistant strain).</p>
                  </list-item>
                  <list-item>
                     <label>2.</label>
                     <p>PPI, AM, metronidazole (ME) (CL-resistant strain).</p>
                  </list-item>
                  <list-item>
                     <label>3.</label>
                     <p>PPI, AM, CL (ME-resistant strain).</p>
                  </list-item>
                  <list-item>
                     <label>4.</label>
                     <p>PPI, AM (high-dose) (<xref ref-type="table" rid="en-table1">Table 1</xref>), ME (CL- and ME-resistant strain).</p>
                  </list-item>
                  <list-item>
                     <label>5.</label>
                     <p>PPI, AM (high-dose) (<xref ref-type="table" rid="en-table1">Table 1</xref>), ME (strain sensitivity test not available).</p>
                  </list-item>
               </list>
               <p>The effectiveness of therapy depends to the largest extent on the antibiotic sensitivity of the isolated strain. In Slovenia, the rate of resistance to CL in children exceeds 20 %; it is slightly lower for the adult population. ME resistance rate of &gt; 20 % is found in both children and adults (<xref ref-type="bibr" rid="en-b19">19</xref>,<xref ref-type="bibr" rid="en-b21">21</xref>,<xref ref-type="bibr" rid="en-b22">22</xref>). When data on antibiotic susceptibility are not available, CL is not included in the first-line therapy because of the high CL-resistance rate reported for the paediatric population in Slovenia.</p>
               <p>Sequential regimen is one of the treatment options in patients infected with <italic toggle="yes">H.pylori. </italic>It consists of a 10-day treatment comprising PPI and AM for the first five days, followed by a combination of CL and ME for the remaining five days. A 10-day sequential regimen has not proved effective in children infected with CL resistant bacterial strain. It can be used as an alternative therapy to the recommended first-line treatment with PPI, AM and CL for children infected with a bacterial strain that is not resistant neither to ME nor to CL.</p>
               <p>The eradication regimen comprising a bismuth preparation (PPI, two antibiotics) can be prescribed in children as an alternative regimen for double resistant strains, or in case bacterial strain culture is not available.</p>
               <p>Most meta-analyses investigating the role of probiotics in the treatment of <italic toggle="yes">H.pylori </italic>infection in adults showed that including adequate amounts of specific probiotic preparations in standard eradication regimens has beneficial effects on the success rate of bacterial eradication (<xref ref-type="bibr" rid="en-b23">23</xref>). The role that probiotic supplementation may play in improving the efficacy of eradication and decreasing the incidence of eradication therapy-related side effect in children has not yet been clarified. For now, there is not enough high-quality research to support the use of supplementary probiotics in the standard treatment of children with specific probiotic bacterial strains.</p>
            </sec>
            <sec id="en-s5.2"
                 sec-type="H.pylori treatment in children not responding to first-line therapy">
               <label>5.2</label>
               <title>H.pylori treatment in children not responding to first-line therapy</title>
               <p>The efficacy of treatment should always be assessed using an appropriate urea breath test or monoclonal stool antigen test. When treatment failure is confirmed, switching to a new eradication regimen is necessary. In the paediatric population, fewer treatment options are available than in adults, which makes choosing the most appropriate first-line therapy even more important.</p>
               <p>Guidelines for a 14-day second-line treatment, depending on the antibiotic susceptibility of bacterial strains and the first-line eradication regimen:</p>
               <p>1.PPI, AM, ME (non-resistant bacterial strain; first-line therapy included PPI, AK, CL)</p>
               <list>
                  <list-item>
                     <label>2.</label>
                     <p>PPI, AM, CL (non-resistant bacterial strain; first-line therapy included PPI, AM, ME)</p>
                  </list-item>
                  <list-item>
                     <label>3.</label>
                     <p>PPI, AM (high-dose; see <xref ref-type="table" rid="en-table1">Table 1</xref>), ME or repeat endoscopy (therapy based on antibiotic sensitivity test results), (non-resistant bacterial strain; first-line treatment - sequential regimen).</p>
                  </list-item>
                  <list-item>
                     <label>4.</label>
                     <p>PPI, AM (high-dose;see <xref ref-type="table" rid="en-table1">Table 1</xref>), ME (CL-resistant bacterial strain; first-line treatment included PPI, AM, ME).</p>
                  </list-item>
                  <list-item>
                     <label>5.</label>
                     <p>PPI, AM (high-dose, see <xref ref-type="table" rid="en-table1">Table 1</xref>), ME or repeat endoscopy (further treatment based on antibiotic sensitivity testing results); (ME-resistant strain; first-line therapy included PPI. AM, CL).</p>
                  </list-item>
                  <list-item>
                     <label>6.</label>
                     <p>PPI, AM (high-dose; see <xref ref-type="table" rid="en-table1">Table 1</xref>). ME or repeat endoscopy (further treatment based on the results of antibiotic sensitivity testing), (antibiotic sensitivity test not available, first-line treatment included PPI, two antibiotics).</p>
                  </list-item>
               </list>
               <p>After failure of the first-line eradication, it is mandatory that the second-line regimen is determined on the basis of antibiotic sensitivity tests and initial therapy. Studies in adult patients have demonstrated that it is sensible to increase the dose of PPI and ME (<xref ref-type="bibr" rid="en-b24">24</xref>). In children, PPI in doses higher than those recommended in the 2011 guidelines, was included already in the first-line regimen (<xref ref-type="bibr" rid="en-b25">25</xref>). According to a study published in 2011, high-dose PPI in AM should be given to children with bacterial strains resistant to ME and CL. These recommendations were taken into account in proposing <italic toggle="yes">H.pylori </italic>treatment modalities (<xref ref-type="bibr" rid="en-b26">26</xref>).</p>
            </sec>
         </sec>
         <sec id="en-s6" sec-type="Conclusions">
            <label>6</label>
            <title>Conclusions</title>
            <p>The efficacy of <italic toggle="yes">H.pylor </italic>infection treatment was well below the recommended level of 90 %. These findings underscore the importance of selecting a 14-day eradication regimen on the basis of the infecting strain antibiotic sensitivity. High-dose PPI should be used. Before initiating treatment, the child or the child‘s parents should be given a detailed explanation of the treatment plan stressing the importance of full adherence to the prescribed medications. Treatment with CL is indicated in patients who are confirmedly not infected with a CL-resistant bacterial strain.When antibiotic susceptibility of a given bacterial strain is not known, or testing cannot be performed, a triple therapy including high-dose PPI, ME and AM is prescribed. One month after the completion of treatment, urea breath test or stool antigen test for <italic toggle="yes">H.pylori </italic>should be done to assess the efficacy of eradication therapy. Selecting appropriate eradication regimen after failure of the first-line treatment is not easy: only a limited number of antibiotics are available for paediatric use, and there is a paucity of relevant studies of more complex eradiction regimens for children.</p>
            <p>Studies of new treatment modalities, such as prospective bismuth-containing treatment, triple antibiotic therapy and treatment with specific probiotic strains would help us optimise second-line eradication regimens for children. Last but not least, the development of vaccine against <italic toggle="yes">H.pylori</italic> infection holds great promise for the future.</p>
         </sec>
      </body>
      <back>
         <ref-list>
            <ref id="en-b1">
               <label>1. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Jones</surname>
                        <given-names>NL</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Koletzko</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Goodman</surname>
                        <given-names>K</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bontems</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Cadranel</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Casswall</surname>
                        <given-names>T</given-names>
                     </name>, 
                        <etal>et al</etal>; 
                        <collab>ESPGHAN, NASPGHAN</collab>
                    </person-group>. 
                    <article-title>Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016)</article-title>. 
                    <source>J Pediatr Gastroenterol Nutr</source>. 
                    <year>2017</year>
                    <month>Jun</month>;
                    <volume>64</volume>(
                    <issue>6</issue>):
                    <fpage>991</fpage>–
                    <lpage>1003</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/MPG.0000000000001594</pub-id>
                    <pub-id pub-id-type="pmid">28541262</pub-id>
                    <issn>0277-2116</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b2">
               <label>2. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Homan</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Hojsak</surname>
                        <given-names>I</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kolaček</surname>
                        <given-names>S</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Helicobacter pylori in pediatrics</article-title>. 
                    <source>Helicobacter</source>. 
                    <year>2012</year>
                    <month>Sep</month>;
                    <volume>17</volume>
                    <supplement>Suppl 1</supplement>:
                    <fpage>43</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1523-5378.2012.00982.x</pub-id>
                    <pub-id pub-id-type="pmid">22958155</pub-id>
                    <issn>1083-4389</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b3">
               <label>3. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Sierra</surname>
                        <given-names>MS</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Hastings</surname>
                        <given-names>EV</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Goodman</surname>
                        <given-names>KJ</given-names>
                     </name>
                    </person-group>. 
                    <article-title>What do we know about benefits of H. pylori treatment in childhood?</article-title>
                    <source>Gut Microbes</source>. 
                    <year>2013</year>
                    <month>Nov-Dec</month>;
                    <volume>4</volume>(
                    <issue>6</issue>):
                    <fpage>549</fpage>–
                    <lpage>67</lpage>. 
                    <pub-id pub-id-type="doi">10.4161/gmic.27000</pub-id>
                    <pub-id pub-id-type="pmid">24280768</pub-id>
                    <issn>1949-0976</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b4">
               <label>4. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Graham</surname>
                        <given-names>DY</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Fischbach</surname>
                        <given-names>L</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Helicobacter pylori treatment in the era of increasing antibiotic resistance</article-title>. 
                    <source>Gut</source>. 
                    <year>2010</year>
                    <month>Aug</month>;
                    <volume>59</volume>(
                    <issue>8</issue>):
                    <fpage>1143</fpage>–
                    <lpage>53</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/gut.2009.192757</pub-id>
                    <pub-id pub-id-type="pmid">20525969</pub-id>
                    <issn>0017-5749</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b5">
               <label>5. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Spee</surname>
                        <given-names>LA</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Madderom</surname>
                        <given-names>MB</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Pijpers</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>van Leeuwen</surname>
                        <given-names>Y</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Berger</surname>
                        <given-names>MY</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Association between helicobacter pylori and gastrointestinal symptoms in children</article-title>. 
                    <source>Pediatrics</source>. 
                    <year>2010</year>
                    <month>Mar</month>;
                    <volume>125</volume>(
                    <issue>3</issue>):
                    <fpage>e651</fpage>–
                    <lpage>69</lpage>. 
                    <pub-id pub-id-type="doi">10.1542/peds.2010-0941</pub-id>
                    <pub-id pub-id-type="pmid">20156901</pub-id>
                    <issn>0031-4005</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b6">
               <label>6. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Holster</surname>
                        <given-names>IL</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Vila</surname>
                        <given-names>AM</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Caudri</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>den Hoed</surname>
                        <given-names>CM</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Perez-Perez</surname>
                        <given-names>GI</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Blaser</surname>
                        <given-names>MJ</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The impact of Helicobacter pylori on atopic disorders in childhood</article-title>. 
                    <source>Helicobacter</source>. 
                    <year>2012</year>
                    <month>Jun</month>;
                    <volume>17</volume>(
                    <issue>3</issue>):
                    <fpage>232</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1523-5378.2012.00934.x</pub-id>
                    <pub-id pub-id-type="pmid">22515362</pub-id>
                    <issn>1083-4389</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b7">
               <label>7. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Feydt-Schmidt</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kindermann</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Konstantopoulos</surname>
                        <given-names>N</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Demmelmair</surname>
                        <given-names>H</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Ballauff</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Findeisen</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Reinfection rate in children after successful Helicobacter pylori eradication</article-title>. 
                    <source>Eur J Gastroenterol Hepatol</source>. 
                    <year>2002</year>
                    <month>Oct</month>;
                    <volume>14</volume>(
                    <issue>10</issue>):
                    <fpage>1119</fpage>–
                    <lpage>23</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/00042737-200210000-00013</pub-id>
                    <pub-id pub-id-type="pmid">12362103</pub-id>
                    <issn>0954-691X</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b8">
               <label>8. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Bontems</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kalach</surname>
                        <given-names>N</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Vanderpas</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Iwanczak</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Casswall</surname>
                        <given-names>T</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Koletzko</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Helicobacter pylori Infection in European children with gastro-duodenal ulcers and erosions</article-title>. 
                    <source>Pediatr Infect Dis J</source>. 
                    <year>2013</year>
                    <month>Dec</month>;
                    <volume>32</volume>(
                    <issue>12</issue>):
                    <fpage>1324</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/INF.0000000000000005</pub-id>
                    <pub-id pub-id-type="pmid">24569306</pub-id>
                    <issn>0891-3668</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b9">
               <label>9. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Brito</surname>
                        <given-names>HS</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Braga</surname>
                        <given-names>JA</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Loggetto</surname>
                        <given-names>SR</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Machado</surname>
                        <given-names>RS</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Granato</surname>
                        <given-names>CF</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kawakami</surname>
                        <given-names>E</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Helicobacter pylori infection &amp; immune thrombocytopenic purpura in children and adolescents: A randomized controlled trial</article-title>. 
                    <source>Platelets</source>. 
                    <year>2015</year>;
                    <volume>26</volume>(
                    <issue>4</issue>):
                    <fpage>336</fpage>–
                    <lpage>41</lpage>. 
                    <pub-id pub-id-type="doi">10.3109/09537104.2014.911836</pub-id>
                    <pub-id pub-id-type="pmid">24832381</pub-id>
                    <issn>0953-7104</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b10">
               <label>10. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Russo</surname>
                        <given-names>G</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Miraglia</surname>
                        <given-names>V</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Branciforte</surname>
                        <given-names>F</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Matarese</surname>
                        <given-names>SM</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Zecca</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bisogno</surname>
                        <given-names>G</given-names>
                     </name>, 
                        <etal>et al</etal>; 
                        <collab>AIEOP-ITP Study Group</collab>
                    </person-group>. 
                    <article-title>Effect of eradication of Helicobacter pylori in children with chronic immune thrombocytopenia: a prospective, controlled, multicenter study</article-title>. 
                    <source>Pediatr Blood Cancer</source>. 
                    <year>2011</year>
                    <month>Feb</month>;
                    <volume>56</volume>(
                    <issue>2</issue>):
                    <fpage>273</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/pbc.22770</pub-id>
                    <pub-id pub-id-type="pmid">20830773</pub-id>
                    <issn>1545-5009</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b11">
               <label>11. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Ferrara</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Capozzi</surname>
                        <given-names>L</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Russo</surname>
                        <given-names>R</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Effect of Helicobacter pylori eradication on platelet count in children with chronic idiopathic thrombocytopenic purpura</article-title>. 
                    <source>Hematology</source>. 
                    <year>2009</year>
                    <month>Oct</month>;
                    <volume>14</volume>(
                    <issue>5</issue>):
                    <fpage>282</fpage>–
                    <lpage>5</lpage>. 
                    <pub-id pub-id-type="doi">10.1179/102453309X12473408860181</pub-id>
                    <pub-id pub-id-type="pmid">19843384</pub-id>
                    <issn>1607-8454</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b12">
               <label>12. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Homan</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Luzar</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kocjan</surname>
                        <given-names>BJ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Orel</surname>
                        <given-names>R</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Mocilnik</surname>
                        <given-names>T</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Shrestha</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Prevalence and clinical relevance of cagA, vacA, and iceA genotypes of Helicobacter pylori isolated from Slovenian children</article-title>. 
                    <source>J Pediatr Gastroenterol Nutr</source>. 
                    <year>2009</year>
                    <month>Sep</month>;
                    <volume>49</volume>(
                    <issue>3</issue>):
                    <fpage>289</fpage>–
                    <lpage>96</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/MPG.0b013e31818f09f2</pub-id>
                    <pub-id pub-id-type="pmid">19525870</pub-id>
                    <issn>0277-2116</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b13">
               <label>13. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Homan</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Šterbenc</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kocjan</surname>
                        <given-names>BJ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Luzar</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Zidar</surname>
                        <given-names>N</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Orel</surname>
                        <given-names>R</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Prevalence of the Helicobacter pylori babA2 gene and correlation with the degree of gastritis in infected Slovenian children</article-title>. 
                    <source>Antonie van Leeuwenhoek</source>. 
                    <year>2014</year>
                    <month>Oct</month>;
                    <volume>106</volume>(
                    <issue>4</issue>):
                    <fpage>637</fpage>–
                    <lpage>45</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s10482-014-0234-0</pub-id>
                    <pub-id pub-id-type="pmid">25055876</pub-id>
                    <issn>0003-6072</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b14">
               <label>14. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Thankachan</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Muthayya</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Sierksma</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Eilander</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Thomas</surname>
                        <given-names>T</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Duchateau</surname>
                        <given-names>GS</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Helicobacter pylori infection does not influence the efficacy of iron and vitamin B(12) fortification in marginally nourished Indian children</article-title>. 
                    <source>Eur J Clin Nutr</source>. 
                    <year>2010</year>
                    <month>Oct</month>;
                    <volume>64</volume>(
                    <issue>10</issue>):
                    <fpage>1101</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/ejcn.2010.126</pub-id>
                    <pub-id pub-id-type="pmid">20683455</pub-id>
                    <issn>0954-3007</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b15">
               <label>15. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Goodman</surname>
                        <given-names>KJ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Correa</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Mera</surname>
                        <given-names>R</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Yepez</surname>
                        <given-names>MC</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Cerón</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Campo</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Effect of Helicobacter pylori infection on growth velocity of school-age Andean children</article-title>. 
                    <source>Epidemiology</source>. 
                    <year>2011</year>
                    <month>Jan</month>;
                    <volume>22</volume>(
                    <issue>1</issue>):
                    <fpage>118</fpage>–
                    <lpage>26</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/EDE.0b013e3181fe7e31</pub-id>
                    <pub-id pub-id-type="pmid">21068668</pub-id>
                    <issn>1044-3983</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b16">
               <label>16. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Rimbara</surname>
                        <given-names>E</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Sasatsu</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Graham</surname>
                        <given-names>DY</given-names>
                     </name>
                    </person-group>. 
                    <article-title>PCR detection of Helicobacter pylori in clinical samples</article-title>. 
                    <source>Methods Mol Biol</source>. 
                    <year>2013</year>;
                    <volume>943</volume>:
                    <fpage>279</fpage>–
                    <lpage>87</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/978-1-60327-353-4_19</pub-id>
                    <pub-id pub-id-type="pmid">23104297</pub-id>
                    <issn>1064-3745</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b17">
               <label>17. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Leal</surname>
                        <given-names>YA</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Flores</surname>
                        <given-names>LL</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Fuentes-Pananá</surname>
                        <given-names>EM</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Cedillo-Rivera</surname>
                        <given-names>R</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Torres</surname>
                        <given-names>J</given-names>
                     </name>
                    </person-group>. 
                    <article-title>13C-urea breath test for the diagnosis of Helicobacter pylori infection in children: a systematic review and meta-analysis</article-title>. 
                    <source>Helicobacter</source>. 
                    <year>2011</year>
                    <month>Aug</month>;
                    <volume>16</volume>(
                    <issue>4</issue>):
                    <fpage>327</fpage>–
                    <lpage>37</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1523-5378.2011.00863.x</pub-id>
                    <pub-id pub-id-type="pmid">21762274</pub-id>
                    <issn>1083-4389</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b18">
               <label>18. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Graham</surname>
                        <given-names>DY</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Lee</surname>
                        <given-names>YC</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Wu</surname>
                        <given-names>MS</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence</article-title>. 
                    <source>Clin Gastroenterol Hepatol</source>. 
                    <year>2014</year>;
                    <volume>12</volume>:(
                    <issue>2</issue>):
                    <fpage>177</fpage>-
                    <lpage>86.e3</lpage>
                    <issn>1542-3565</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b19">
               <label>19. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Butenko</surname>
                        <given-names>T</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Jeverica</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Orel</surname>
                        <given-names>S</given-names>
                     </name>,
                        <name name-style="western">
                        <surname>Homan</surname>
                        <given-names>M</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Antibacterial resistance and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian childrene</article-title>. 
                    <source>Helicobacter</source>. 
                    <year>2017</year>;
                    <volume>22</volume>:(
                    <issue>5</issue>):
                    <fpage>e12400</fpage>
                    <pub-id pub-id-type="doi">10.1111/hel.12400</pub-id>
                    <pub-id pub-id-type="pmid">28653787</pub-id>
                    <issn>1083-4389</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b20">
               <label>20. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Schwarzer</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bontems</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Urruzuno</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kalach</surname>
                        <given-names>N</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Iwanczak</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Roma-Giannikou</surname>
                        <given-names>E</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Sequential Therapy for Helicobacter pylori Infection in Treatment-naïve Children</article-title>. 
                    <source>Helicobacter</source>. 
                    <year>2016</year>
                    <month>Apr</month>;
                    <volume>21</volume>(
                    <issue>2</issue>):
                    <fpage>106</fpage>–
                    <lpage>13</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/hel.12240</pub-id>
                    <pub-id pub-id-type="pmid">26123402</pub-id>
                    <issn>1083-4389</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b21">
               <label>21. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Tepeš</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Vujasinović</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Šeruga</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Stefanovič</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Forte</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Jeverica</surname>
                        <given-names>S</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication</article-title>. 
                    <source>Eur J Gastroenterol Hepatol</source>. 
                    <year>2016</year>
                    <month>Jun</month>;
                    <volume>28</volume>(
                    <issue>6</issue>):
                    <fpage>676</fpage>–
                    <lpage>83</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/MEG.0000000000000590</pub-id>
                    <pub-id pub-id-type="pmid">26862930</pub-id>
                    <issn>0954-691X</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b22">
               <label>22. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Jeverica</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Tepeš</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Ihan</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Skvarč</surname>
                        <given-names>M</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Primarna odpornost bakterije Helicobacter pylori</article-title>. 
                    <source>Zdrav Vestn</source>. 
                    <year>2010</year>;
                    <volume>79</volume>:(
                    <issue>1</issue>):
                    <fpage>25</fpage>–
                    <lpage>30</lpage>.
                    <issn>0350-0063</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b23">
               <label>23. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Zhu</surname>
                        <given-names>R</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Chen</surname>
                        <given-names>K</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Zheng</surname>
                        <given-names>YY</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Zhang</surname>
                        <given-names>HW</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Wang</surname>
                        <given-names>JS</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Xia</surname>
                        <given-names>YJ</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy</article-title>. 
                    <source>World J Gastroenterol</source>. 
                    <year>2014</year>
                    <month>Dec</month>;
                    <volume>20</volume>(
                    <issue>47</issue>):
                    <fpage>18013</fpage>–
                    <lpage>21</lpage>. 
                    <pub-id pub-id-type="doi">10.3748/wjg.v20.i47.18013</pub-id>
                    <pub-id pub-id-type="pmid">25548501</pub-id>
                    <issn>1007-9327</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b24">
               <label>24. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Molina-Infante</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Lucendo</surname>
                        <given-names>AJ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Angueira</surname>
                        <given-names>T</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Rodriguez-Tellez</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Perez-Aisa</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Balboa</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <etal>et al</etal>; 
                        <collab>European Registry on H. pylori management (Hp‐EuReg)</collab>
                    </person-group>. 
                    <article-title>Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study</article-title>. 
                    <source>Aliment Pharmacol Ther</source>. 
                    <year>2015</year>
                    <month>Mar</month>;
                    <volume>41</volume>(
                    <issue>6</issue>):
                    <fpage>581</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/apt.13069</pub-id>
                    <pub-id pub-id-type="pmid">25776067</pub-id>
                    <issn>0269-2813</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b25">
               <label>25. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Koletzko</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Jones</surname>
                        <given-names>NL</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Goodman</surname>
                        <given-names>KJ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Gold</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Rowland</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Cadranel</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <etal>et al</etal>; 
                        <collab>H pylori Working Groups of ESPGHAN and NASPGHAN</collab>
                    </person-group>. 
                    <article-title>Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children</article-title>. 
                    <source>J Pediatr Gastroenterol Nutr</source>. 
                    <year>2011</year>
                    <month>Aug</month>;
                    <volume>53</volume>(
                    <issue>2</issue>):
                    <fpage>230</fpage>–
                    <lpage>43</lpage>.
                    <pub-id pub-id-type="pmid">21558964</pub-id>
                    <issn>1536-4801</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b26">
               <label>26. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Schwarzer</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bontems</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Urruzuno</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kalach</surname>
                        <given-names>N</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Iwanczak</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Roma-Giannikou</surname>
                        <given-names>E</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Sequential Therapy for Helicobacter pylori Infection in Treatment-naïve Children</article-title>. 
                    <source>Helicobacter</source>. 
                    <year>2016</year>
                    <month>Apr</month>;
                    <volume>21</volume>(
                    <issue>2</issue>):
                    <fpage>106</fpage>–
                    <lpage>13</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/hel.12240</pub-id>
                    <pub-id pub-id-type="pmid">26123402</pub-id>
                    <issn>1083-4389</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b27">
               <label>27. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Zeng</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Mao</surname>
                        <given-names>XH</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Li</surname>
                        <given-names>JX</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Tong</surname>
                        <given-names>WD</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Wang</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Zhang</surname>
                        <given-names>YJ</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial</article-title>. 
                    <source>Lancet</source>. 
                    <year>2015</year>
                    <month>Oct</month>;
                    <volume>386</volume>(
                    <issue>10002</issue>):
                    <fpage>1457</fpage>–
                    <lpage>64</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S0140-6736(15)60310-5</pub-id>
                    <pub-id pub-id-type="pmid">26142048</pub-id>
                    <issn>0140-6736</issn>
                </mixed-citation>
            </ref>
         </ref-list>
      </back>
   </sub-article>
</article>
